Primary Glioblastoma Clinical Trial
Official title:
An Interventional, Non-randomized, Phase 1/2, Light Dose-escalation Study to Investigate the Safety and Feasibility of Intraoperative Photodynamic Therapy (PDT) With Pentalafen® Drug and Heliance®Solution Device in Male and Female Patients 18 to 69 Years of Age With Grade IV Glioblastoma
The primary objective of this clinical trial is to determine the safety and tolerability of two doses of light in intraoperative PDT added to standard of care; temozolomide-based chemotherapy in male and female patients aged 18 to 69 with newly diagnosed glioblastoma. This treatment will be carried out in addition to the maximal surgical resection. Data collected during this trial will be used to design the upcoming pivotal study . The study will utilize an independent Data and Safety Monitoring Board (iDSMB) that will review safety data to allow dose escalation.
This study is a non randomized, open label, single center , phase 1/2 trial with a sequential enrollment in a 3+3 dose escalation design to establish the maximal tolerated dose of light (MTD). The dose of light will be escalated in successive cohorts of patients until at least 1 patient experiences a dose-limiting toxicity (DLT). A DLT is defined as any grade ≥ 3 Adverse Event (AE), or any relevant grade 2 AE of Central Nervous System or any Serious Adverse Events (SAEs) possibly, probably or definitively related to the intraoperative PDT (i.e., 5-aminolevulinic acid hydrochloride (5-ALA HCl) administration + brain cavity illumination), for which the onset date is within 28 days after the procedure, and where conservative therapy fails and surgical is required, according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. After dose escalation patient will be followed in the standard of care until visit at 6 months to evaluate the progression free survival. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01165671 -
Carbon Ion Radiotherapy for Primary Glioblastoma
|
N/A | |
| Not yet recruiting |
NCT05100641 -
AV-GBM-1 vs Control as Adjunctive Therapy Following Surgery and RT/TMZ in Newly Diagnosed GBM
|
Phase 3 | |
| Active, not recruiting |
NCT04250922 -
LAM561 With RT and TMZ for Adults With Glioblastoma
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05318612 -
Effectiveness of MR-guided LITT Therapy in Irresectable Glioblastoma (EMITT)
|
Phase 3 |